Mukund, K.; Alva-Ornelas, J.A.; Maddox, A.L.; Murali, D.; Veraksa, D.; Saftics, A.; Tomsic, J.; Frankhouser, D.; Razo, M.; Jovanovic-Talisman, T.;
et al. Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance. Cancers 2024, 16, 553.
https://doi.org/10.3390/cancers16030553
AMA Style
Mukund K, Alva-Ornelas JA, Maddox AL, Murali D, Veraksa D, Saftics A, Tomsic J, Frankhouser D, Razo M, Jovanovic-Talisman T,
et al. Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance. Cancers. 2024; 16(3):553.
https://doi.org/10.3390/cancers16030553
Chicago/Turabian Style
Mukund, Kavitha, Jackelyn A. Alva-Ornelas, Adam L. Maddox, Divya Murali, Darya Veraksa, Andras Saftics, Jerneja Tomsic, David Frankhouser, Meagan Razo, Tijana Jovanovic-Talisman,
and et al. 2024. "Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance" Cancers 16, no. 3: 553.
https://doi.org/10.3390/cancers16030553
APA Style
Mukund, K., Alva-Ornelas, J. A., Maddox, A. L., Murali, D., Veraksa, D., Saftics, A., Tomsic, J., Frankhouser, D., Razo, M., Jovanovic-Talisman, T., Seewaldt, V. L., & Subramaniam, S.
(2024). Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance. Cancers, 16(3), 553.
https://doi.org/10.3390/cancers16030553
